Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + chlorphenamine + phenylephrine
- Development stage
- Phase 3
- Lead developer
- Carnot Laboratorios
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rinofren is an over-the-counter (OTC) multi-symptom cold and flu medication developed and marketed by Carnot Laboratorios. It is a combination product containing paracetamol (an analgesic and antipyretic), chlorphenamine maleate (a first-generation antihistamine), and phenylephrine hydrochloride (a sympathomimetic decongestant). It is indicated for the symptomatic relief of the common cold and influenza, addressing symptoms such as fever, body aches, nasal congestion, and sneezing. The product is primarily available in Mexico and other Latin American markets as an "antigripal" treatment.
- Brand names
- Rinofren
- Other names
- Rinofren
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)COX
Beyond the preview
Go deeper on paracetamol + chlorphenamine + phenylephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + chlorphenamine + phenylephrine.